156 related articles for article (PubMed ID: 34245344)
21. Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer.
Lammoglia JJ; Mericq V
Horm Res; 2009; 71(3):178-84. PubMed ID: 19188744
[TBL] [Abstract][Full Text] [Related]
22. Use of Teriparatide in Hyperphosphatemic Familial Tumor Calcinosis: Evaluating the Interaction Between FGF23 and PTH on the Phosphaturic Effect.
Pallone SG; Kunii IS; da Silva REC; Lazaretti-Castro M
Calcif Tissue Int; 2022 Jul; 111(1):102-106. PubMed ID: 35338393
[TBL] [Abstract][Full Text] [Related]
23. Hyperphosphatemic tumoral calcinosis: a 10-year follow-up.
Alves C; Lima R
J Pediatr Endocrinol Metab; 2011; 24(1-2):25-7. PubMed ID: 21528811
[TBL] [Abstract][Full Text] [Related]
24. Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.
Folsom LJ; Imel EA
Curr Osteoporos Rep; 2015 Apr; 13(2):78-87. PubMed ID: 25656441
[TBL] [Abstract][Full Text] [Related]
25. Hyperphosphatemic Tumoral Calcinosis With Pemigatinib Use.
Puar A; Donegan D; Helft P; Kuhar M; Webster J; Rao M; Econs M
AACE Clin Case Rep; 2022; 8(5):217-220. PubMed ID: 36189136
[TBL] [Abstract][Full Text] [Related]
26. FGF23-S129F mutant bypasses ER/Golgi to the circulation of hyperphosphatemic familial tumoral calcinosis patients.
Shawar SM; Ramadan AR; Ali BR; Alghamdi MA; John A; Hudaib FM
Bone; 2016 Dec; 93():187-195. PubMed ID: 26620085
[TBL] [Abstract][Full Text] [Related]
27. Root anomalies and dentin dysplasia in autosomal recessive hyperphosphatemic familial tumoral calcinosis (HFTC).
Vieira AR; Lee M; Vairo F; Loguercio Leite JC; Munerato MC; Visioli F; D'Ávila SR; Wang SK; Choi M; Simmer JP; Hu JC
Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Dec; 120(6):e235-9. PubMed ID: 26337219
[TBL] [Abstract][Full Text] [Related]
28. Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations.
Ichikawa S; Baujat G; Seyahi A; Garoufali AG; Imel EA; Padgett LR; Austin AM; Sorenson AH; Pejin Z; Topouchian V; Quartier P; Cormier-Daire V; Dechaux M; Malandrinou FCh; Singhellakis PN; Le Merrer M; Econs MJ
Am J Med Genet A; 2010 Apr; 152A(4):896-903. PubMed ID: 20358599
[TBL] [Abstract][Full Text] [Related]
29. Familial hyperphosphatemic tumoral calcinosis in an unusual and usual sites and dramatic improvement with the treatment of acetazolamide, sevelamer and topical sodium thiosulfate.
Emecen Sanli M; Kilic A; Aktasoglu E; Inci A; Okur I; Ezgu F; Tumer L
J Pediatr Endocrinol Metab; 2021 Jun; 34(6):813-816. PubMed ID: 33819418
[TBL] [Abstract][Full Text] [Related]
30. A Sole Case of the FGF23 Gene Mutation c.202A>G (p.Thr68Ala) Associated with Multiple Severe Vascular Aneurysms and a Hyperphosphatemic Variant of Tumoral Calcinosis-A Case Report.
Ivanova NG
Life (Basel); 2024 May; 14(5):. PubMed ID: 38792634
[TBL] [Abstract][Full Text] [Related]
31. Nonfamilial hyperphosphatemic tumoral calcinosis with ulnar neuropathy.
Shetty GM; Murari AS; Shah SV; Dhengle S
Joint Bone Spine; 2009 Mar; 76(2):198-201. PubMed ID: 19073370
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic success of sodium thiosulfate in treating cutaneous calciphylaxis in a patient with hyperphosphataemic familial tumoral calcinosis.
Requena S; Santos-Juanes J; Morales P; Gómez C
Australas J Dermatol; 2022 Feb; 63(1):e75-e77. PubMed ID: 34817065
[TBL] [Abstract][Full Text] [Related]
33. [Vascular Calcification - Pathological Mechanism and Clinical Application - . Regulation of mineral metabolism and mineralization by FGF23].
Fukumoto S
Clin Calcium; 2015 May; 25(5):687-91. PubMed ID: 25926572
[TBL] [Abstract][Full Text] [Related]
34. Hyperphosphatemic familial tumoral calcinosis caused by a novel variant in the GALNT3 gene.
Mahjoubi F; Ghadir M; Samanian S; Heydari I; Honardoost M
J Endocrinol Invest; 2020 Aug; 43(8):1125-1130. PubMed ID: 32125652
[TBL] [Abstract][Full Text] [Related]
35. Severe vascular calcification and tumoral calcinosis in a family with hyperphosphatemia: a fibroblast growth factor 23 mutation identified by exome sequencing.
Shah A; Miller CJ; Nast CC; Adams MD; Truitt B; Tayek JA; Tong L; Mehtani P; Monteon F; Sedor JR; Clinkenbeard EL; White K; Mehrotra R; LaPage J; Dickson P; Adler SG; Iyengar SK
Nephrol Dial Transplant; 2014 Dec; 29(12):2235-43. PubMed ID: 25378588
[TBL] [Abstract][Full Text] [Related]
36. Clinical and genetic analysis of idiopathic normophosphatemic tumoral calcinosis in 19 patients.
Zuo QY; Cao X; Liu BY; Yan D; Xin Z; Niu XH; Li C; Deng W; Dong ZY; Yang JK
J Endocrinol Invest; 2020 Feb; 43(2):173-183. PubMed ID: 31535357
[TBL] [Abstract][Full Text] [Related]
37. [Hyperphosphatemic pseudotumoral calcinosis due to FGF23 mutation with secondary amyloidosis].
Sottini L; Veniero P; De Gaetano A; Olivi L; Brunori G
G Ital Nefrol; 2022 Aug; 39(4):. PubMed ID: 36073335
[TBL] [Abstract][Full Text] [Related]
38. Hyperphosphatemic tumoral calcinosis.
Mallick S; Ahmad Z; Gupta AK; Mathur SR
BMJ Case Rep; 2013 May; 2013():. PubMed ID: 23645700
[TBL] [Abstract][Full Text] [Related]
39. Recurrence of tumoral calcinosis: a case report.
Sandomenico F; Corvino A; Ronza FM; Catalano O; Fazioli F; De Chiara A; Campanino MR; Porcaro M; Tafuri D; Petrillo A
Acta Biomed; 2019 Dec; 90(4):587-594. PubMed ID: 31910191
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
